- Home
- DSGN vs OM Comparison
DSGN vs OM Comparison
Compare DSGN & OM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- OM
- Stock Information
- Founded
- DSGN 2017
- OM 2003
- Country
- DSGN United States
- OM United States
- Employees
- DSGN N/A
- OM N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DSGN Health Care
- OM Health Care
- Exchange
- DSGN Nasdaq
- OM Nasdaq
- Market Cap
- DSGN 208.9M
- OM 247.1M
- IPO Year
- DSGN 2021
- OM 2020
- Fundamental
- Price
- DSGN $5.85
- OM $13.85
- Analyst Decision
- DSGN
- OM Hold
- Analyst Count
- DSGN 0
- OM 1
- Target Price
- DSGN N/A
- OM $22.00
- AVG Volume (30 Days)
- DSGN 167.2K
- OM 151.0K
- Earning Date
- DSGN 11-06-2025
- OM 11-05-2025
- Dividend Yield
- DSGN N/A
- OM N/A
- EPS Growth
- DSGN N/A
- OM N/A
- EPS
- DSGN N/A
- OM N/A
- Revenue
- DSGN N/A
- OM $119,304,000.00
- Revenue This Year
- DSGN N/A
- OM $12.37
- Revenue Next Year
- DSGN N/A
- OM $10.52
- P/E Ratio
- DSGN N/A
- OM N/A
- Revenue Growth
- DSGN N/A
- OM 2.47
- 52 Week Low
- DSGN $2.60
- OM $5.85
- 52 Week High
- DSGN $7.77
- OM $25.35
- Technical
- Relative Strength Index (RSI)
- DSGN 55.18
- OM 46.64
- Support Level
- DSGN $5.65
- OM $13.30
- Resistance Level
- DSGN $6.65
- OM $14.43
- Average True Range (ATR)
- DSGN 0.49
- OM 0.62
- MACD
- DSGN -0.05
- OM 0.14
- Stochastic Oscillator
- DSGN 50.40
- OM 59.15
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.